Alliance Global Partners analyst Ben Haynor downgraded Viveve Medical to Neutral from Buy and dropped coverage of the name after the company announced the pivotal PURSUIT trial in stress urinary incontinence in women did not meet its primary endpoint nor several secondary endpoints. The analyst expects little interest from potential acquirers and sees little upside for shareholders.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIVE: